Completed OBSERVATIONAL NCT02185911

Observational Study of Correction of Anaemia With Darbepoetin Alfa at QM Dosing Interval in Patients With CKD Not on Dialysis (ADAPTATION)

Observational Study of Correction of Anaemia With Darbepoetin Alfa at Monthly Dose Frequency in EU and Australian Patients With Chronic Kidney Disease Not on Dialysis

Sponsor: Amgen

Conditions Anaemia Chronic Kidney Disease (CKD)

Updated 7 times since 2017 Last updated: Mar 4, 2016 Started: Jun 30, 2014 Primary completion: Apr 30, 2015 Completion: Apr 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Anaemia and Chronic Kidney Disease (CKD) and is currently completed. Amgen leads this study, which shows 7 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed
Sep 2024 — Sep 2025 [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Jan 2017 — Apr 2018 [monthly]

Completed NA

First recorded

Jun 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen

Data source: Amgen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albano Laziale RM, Italy , Athens, Greece , Badalona, Spain , Baja, Hungary , Barcelona, Spain , Brno, Czechia , Córdoba, Spain , Dobrich, Bulgaria , Feldkirch, Austria , Havlíčkův Brod, Czechia and 23 more locations